Could you explain how mirdametinib, as a MEK inhibitor, targets NF1-associated plexiform neurofibromas? How does it differ from other treatments currently in use or under development for NF1-PN?

• What were the key considerations and challenges in the development of mirdametinib, especially given the rarity and complexity of NF1-PN?

Based on the Phase 2b ReNeu trial, how effective was mirdametinib in reducing tumor volume in NF1-PN patients? What does the objective response rate signify for this patient population?

• The trial reported significant improvements in pain, quality of life, and physical function. Can you elaborate on these patient-reported outcomes and their importance in NF1-PN treatment?

What insights can you provide about the safety and tolerability of mirdametinib, considering the reported adverse events in the trial?

• How do the safety profiles in pediatric and adult patients compare, and what are the implications for long-term treatment?

How does mirdametinib integrate into the current treatment landscape for NF1-PN? Are there specific patient groups that might benefit most from this therapy?

• What are the broader implications of the ReNeu trial findings for the management of NF1-PN and potentially other manifestations of NF1?

Considering the current treatment options for NF1-PN, where does mirdametinib stand in terms of potential market impact and patient access?

• Are there any other emerging therapies or research developments that could complement or compete with mirdametinib in treating NF1-PN?